Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

909
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
909
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

208
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
208
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

245
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
245
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

788
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
788
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

755
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
755

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial.

Nature medicine·2026
Same author

Response to Letter regarding the article: Iron Deficiency Definitions and their Clinical and Prognostic Associations Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure.

European journal of heart failure·2026
Same author

Phosphoproteomics distinguishes disease-specific mechanisms for human phospholamban cardiomyopathy reversible by RNA therapy.

Signal transduction and targeted therapy·2026
Same author

Proton-Pump Inhibitor Use as a Modifiable Etiological Factor for Iron Deficiency in Heart Failure.

Journal of cardiac failure·2026
Same author

Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in patients with heart failure: the DECISION trial.

European heart journal·2026
Same author

Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial.

Nature medicine·2026

Related Experiment Video

Updated: Jan 12, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.3K

RNA Therapeutics in Heart Failure.

Frederik E Deiman1, Myrthe M de Graaf1, Herman H W Sillje1

  • 1Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Journal of Cardiovascular Translational Research
|October 30, 2025
PubMed
Summary

RNA therapeutics, including small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and messenger RNAs (mRNAs), show promise for treating heart failure (HF). These advanced therapies target key molecular pathways involved in HF pathogenesis, offering new hope for personalized treatment strategies.

Keywords:
Antisense oligonucleotidesCalcium handlingHeart failureInflammationMyocardial fibrosisOxidative stressRNA therapeuticsRNAimiRNAsiRNA

More Related Videos

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.4K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.1K

Related Experiment Videos

Last Updated: Jan 12, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.3K
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.4K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

3.1K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cardiovascular Medicine

Background:

  • Heart failure (HF) pathogenesis involves complex molecular pathways.
  • Current HF treatments have limitations in addressing underlying molecular mechanisms.
  • RNA-based therapeutics offer novel strategies for molecularly targeted interventions.

Purpose of the Study:

  • To review RNA-based therapeutics for heart failure (HF).
  • To detail mechanisms and applications of RNA therapeutics in HF treatment.
  • To identify novel therapeutic targets for HF.

Main Methods:

  • Review of preclinical studies on RNA therapeutics in HF.
  • Analysis of RNA therapeutic mechanisms targeting HF pathways.
  • Exploration of pathological processes in HF amenable to RNA-based interventions.

Main Results:

  • RNA therapeutics can modulate key HF pathological processes like calcium handling, fibrosis, oxidative stress, and inflammation.
  • Preclinical studies demonstrate the potential of siRNAs, ASOs, and mRNAs in HF models.
  • Novel therapeutic targets for HF amenable to RNA-based modulation have been identified.

Conclusions:

  • RNA therapeutics represent a promising next-generation treatment strategy for HF.
  • These therapies offer potential for more precise and personalized HF interventions.
  • RNA-based approaches may help reverse disease progression in HF patients.